10 Stocks Analysts Upgraded On Wednesday

Page 3 of 3

4. Camtek (NASDAQ:CAMT)

Average Upside Potential: 44%

Northland upgraded Camtek to Outperform from Market Perform on November 18 with a $130 price target. The firm pointed to comments on advanced packaging capacity from a major AI chip customer’s earnings call.

Camtek, based in Migdal HaEmek, Israel, makes inspection and metrology equipment that checks chips for defects during manufacturing, including the chips that go into AI systems. In the third quarter of 2026, revenue rose 28% to $161.3 million from $126.0 million in the third quarter of 2025, and non-GAAP earnings were $0.99 per diluted share. Its tools cover the front and mid-end of production up to the beginning of assembly. Chief Executive Officer Rafi Amit said that for the first time in the company’s history it has visibility a year ahead. The company expects revenue of about $180 million in the fourth quarter of 2026. It also gave an initial 2027 outlook of over $800 million.

Advanced packaging is the area Northland is betting on, and the company’s own 2027 outlook is the clearest sign of how much demand it expects there. Analysts expect earnings per share to grow 42.45% next year.

3. SOLV Energy (NASDAQ:MWH)

Average Upside Potential: 45%

UBS analyst Jon Windham upgraded SOLV Energy to Buy from Neutral on November 18, even as he cut the price target to $37 from $50. He argued the market is pricing in too little growth.

SOLV Energy, based in San Diego, designs, builds and maintains utility-scale solar and battery storage projects. In the third quarter of 2026, revenue rose 65% to $1.24 billion. Total backlog reached about $9.2 billion on September 30, 2026, and the company raised both its revenue and adjusted EBITDA guidance for full-year 2026. SOLV said it has more than 24 gigawatts under contract for operations and maintenance, and Chief Executive Officer George Hershman said the company delivered another quarter of strong results, citing execution and a focus on safety.

The stock has not followed the results. It has fallen back toward its IPO price of February 2026 despite acquisitions and rounds of raised guidance, and Windham’s lower target reflects that. UBS argues the market’s expectations for future earnings are too low given the size of the backlog. Margins are thin: the profit margin over the past 12 months was 3.25%.

2. Tandem Diabetes Care (NASDAQ:TNDM)

Average Upside Potential: 60%

Stifel analyst Jonathan Block upgraded Tandem Diabetes Care to Buy from Hold on November 18 and raised his price target to $26 from $22. He called the shares an attractive entry point near the low end of their trailing 12-month range and said channel checks suggest tubeless pumps will take share, which helps the company’s Mobi.

Tandem, based in San Diego, designs insulin pumps for people with diabetes, including the t:slim X2 and the smaller Mobi. In the third quarter of 2026, sales were $283.7 million, with about 33,000 pumps shipped. Gross margin rose 270 basis points from the third quarter of 2025 to 57%, and operating margin improved 830 basis points. Pharmacy-channel sales reached 15% of U.S. sales, part of a shift to a pay-as-you-go model that spreads out what customers pay.

Block also expects the company’s margin to keep improving, but he flagged risks too: competition from other pump makers, adoption of GLP-1 drugs, reimbursement cuts and regulatory hurdles for a patch pump. Tandem still lost money over the past 12 months, with an operating margin of -2.45%.

1. Innoviva (NASDAQ:INVA)

Average Upside Potential: 83%

Piper Sandler started coverage of Innoviva on November 18 with an Overweight rating and a $29 price target. The firm points to the company’s cash-generating hospital brands and royalty streams.

Innoviva describes itself as a diversified holding company. It collects royalties on once-daily inhaled respiratory medicines sold by GSK, including Relvar Breo Ellipta and Anoro Ellipta, and sells hospital drugs through Innoviva Specialty Therapeutics. In the third quarter of 2026, U.S. net product sales at that unit rose 45% to $43.3 million, and royalty revenue from GSK was $58.1 million. The company also bought back shares during the third quarter of 2026 and said it remains on track to meet its 2026 guidance of at least $150 million in U.S. net product sales.

Innoviva also holds strategic investments in other healthcare assets, which is why its reported results can swing with the value of those stakes. Our list of biotech stocks billionaires favor covers more of the industry. The commercial unit’s growth matters because royalty revenue has been flat to lower: GSK royalties were $63.4 million in the third quarter of 2025.

READ NEXT: ExxonMobil (XOM) Trades at a Premium Yet Earnings Are Expected to Shrink and Goldman Sachs (GS) vs Charles Schwab (SCHW): Which is a Better Stock to Buy?

Follow Insider Monkey on Google News.

Page 3 of 3